Showing results (1-10 of 15) with videos related to
Sort By:
Pageof 2
Current Treatment Options in Neurology|March 20, 2012
Emerging disease-modifying therapies in multiple sclerosisJai Perumal, Omar KhanExpert Opinion on Drug Metabolism & Toxicology|November 28, 2006
Glatiramer acetate therapy for multiple sclerosis: a reviewJai Perumal, Massimo Filippi, Corey Ford, et al.Neurology and Therapy|March 26, 2023
Long-Term Effectiveness and Safety of Natalizumab in African American and Hispanic/Latino Patients with Early Relapsing-Remitting Multiple Sclerosis: STRIVE Data AnalysisJai Perumal, Roumen Balabanov, Laura Balcer, et al.BMC Neurology|June 10, 2019
Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVEJai Perumal, Robert J Fox, Roumen Balabanov, et al.Ethnicity & Disease|September 15, 2025
B-Cell-Targeted Therapies for Black vs White Americans with Relapsing Multiple SclerosisRomae Hylton-Gordon, Svetlana Khanin, Yingying Xiong, et al.Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|June 25, 2020
Impact of Lesion Location on Longitudinal Myelin Water Fraction Change in Chronic Multiple Sclerosis LesionsSneha Pandya, Ulrike W Kaunzner, Sandra M Hurtado Rúa, et al.CNS Drugs|September 6, 2022
Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label StudyJai Perumal, Roumen Balabanov, Ray Su, et al.CNS Drugs|February 13, 2023
Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label StudyJai Perumal, Roumen Balabanov, Ray Su, et al.Advances in Therapy|May 20, 2021
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label StudyJai Perumal, Roumen Balabanov, Ray Su, et al.Neurology(R) Neuroimmunology & Neuroinflammation|November 2, 2019
Black African and Latino/a identity correlates with increased plasmablasts in MSKiel M Telesford, Ulrike W Kaunzner, Jai Perumal, et al.Pageof 2